Sopharma AD (WSE:SPH)

Market Cap	4.21B +99.3%
Revenue (ttm)	5.68B +22.6%
Net Income	288.18M +75.0%
EPS	0.84 +154.0%
Shares Out	n/a
PE Ratio	14.60
Forward PE	n/a
Dividend	0.36 (4.98%)
Ex-Dividend Date	Dec 18, 2025

Volume	n/a
Open	7.44
Previous Close	7.30
Day's Range	7.30 - 7.44
52-Week Range	4.10 - 16.00
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1933
• Employees: 5,932
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SPH

Financial Performance

In 2025, Sopharma AD's revenue was 2.63 billion, an increase of 22.57% compared to the previous year's 2.15 billion. Earnings were 133.52 million, an increase of 74.97%.

Financial numbers in BGN